California Life Sciences Association was recently featured in the San Diego Union-Tribune regarding its new study on the impact of international reference pricing. Up to 88 percent fewer new drug approvals projected in study commissioned by Biocom and California Life Sciences Association.
CLSA and Biocom Release Data Showing Anticipated Real-World Impact of Foreign Reference Pricing Proposed by House Democrats in H.R. 3 to Lower Drug Prices
Life Sciences Trade Groups Warn Congress: International Reference Pricing Proposals Included in Bills like H.R. 3 Undermine Hope for Patients and America’s Leadership in Biomedical Innovation
While the 2018 legislative year marked arguably the most successful year ever for CLSA in Sacramento and provided a number of major policy issues on which to focus our energy, the 2019 legislative year was “death by a thousand cuts,” requiring CLSA to spread its attention broadly across a host of issues outside of our traditional areas of focus.
CLSA organized a multi-state life sciences association letter to House and Senate Leadership, expressing our strong concerns with recent legislative proposals that threaten to undermine America’s global leadership in biomedical innovation by introducing international reference pricing or foreign price controls.
On Oct. 22, CLSA, in partnership with Allergan and Edwards Lifesciences, hosted facility tour and roundtable discussion with the nearly 40 personnel, including state legislators, legislative staff, the Orange County Medical Association, and other key stakeholders to educate policymakers and stakeholders on the value of life sciences innovation in Orange County.
On Oct 17, CLSA and Covington & Burling, LLP hosted Keith Flanagan, Director, and Maarika Kimbrell, Deputy Director, of FDA’s Office of New Drugs (OND) for a roundtable discussion on drug development.
California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, has announced that Dr. Jennifer Doudna, a visionary leader in CRISPR gene editing technology and nominee for Nobel Prize in Chemistry, will receive the 2019 Life Sciences Leadership Award, a prestigious award to be presented at CLSA’s 2019 Pantheon DiNA Program. The Pantheon Awards honors California’s most innovative and dedicated life sciences leaders for their ongoing contributions to California’s life sciences sector.
Precision medicine uses some of the world’s most sophisticated technologies to find the root causes of each patient’s unique condition and apply the best, most precise treatments. California is a biomedical juggernaut, and the precision medicine research being funded today will impact patients around the world. Learn how California is leading the way in precision medicine research.
California Life Sciences Association (CLSA), the trade association representing California’s life sciences sector, has announced the 2019 Pantheon DiNATM Awards slate of honorees. Through the premier awards program, CLSA annually recognizes excellence in the California life sciences sector and celebrates the contributions and achievements of leading life sciences innovators in the state.